COMPANY
TECHNOLOGY
INVESTORS
TEAM
CONTACT
HOW IT WORKS
HOW WE MAKE IT
DIRECT
BLOOD SUPPLY
PIPELINE
CANCER
OUR PRODRUGS
TARGETING
PATENTS
PUBLICATIONS
Please click the links below to download pdf
2001 - Design, Synthesis, and Pharmacological Evaluation of Thapsigargin Analogues for Targeting Apoptosis to Prostatic Cancer Cells
2003 - Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer
2006 - Pharmacokinetics, Biodistribution, and Antitumor Efficacy of a Human Glandular Kallikrein 2 (hK2)-Activated Thapsigargin Prodrug
2009 - A Trojan Horse in Drug Development: Targeting of Thapsigargins Toward Prostate Cancer Cells
2009 - Amino Acid Containing Thapsigargin Analogs Deplete Androgen Receptor Protein Via Synthesis Inhibition and Induce the Death of Prostate Cancer Cells